Showing 3811-3820 of 4181 results for "".
- Dermira Completes $51 Million Financing and Expands Management Team and Board of Directorshttps://practicaldermatology.com/news/20140821-dermira_completes_51_million_financing_and_expands_management_team_and_board_of_directors/2459139/Dermira, a specialty biopharmaceutical focused on dermatology, completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock S
- Acyclovir Muco-Adhesive Buccal Tablet Offers a Novel Approach to Target HSVhttps://practicaldermatology.com/news/20140820-acyclovir_muco-adhesive_buccal_tablet_offers_a_novel_approach_to_target_hsv/2459141/Sitavig® (50mg acyclovir) Muco-Adhesive Buccal Tablet is a new treatment option for recurrent herpes labialis, offering a unique vehicle and delivery system. Sitavig, licensed to Innocutis by BioAlliance Pharma, uses proprietary Lauriad® delivery technology, which delivers a high and sustained conce
- Carma Laboratories Introduces New Carmex® Cold Sore Treatmenthttps://practicaldermatology.com/news/20140820-carma_laboratories_introduces_new_carmex_cold_sore_treatment/2459142/Carma Laboratories, Inc., the maker of Carmex® lip balm products, has launched the new Carmex® Cold Sore Treatment. This product features TriPLEX™ Formula advanced technology, which combines three different optical brightener and filler technologies that each provide unique appea
- Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, And Sinopharm A-Think Pharmaceutical Co., LTDhttps://practicaldermatology.com/news/20140818-provectus_signs_memorandum_of_understanding_with_sinopharm-china_state_institute_of_pharmaceutical_industry_and_sinopharm_a-think_pharmaceutical_co_lt/2459143/Negotiations on Licensing PV-10 in China Opened Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it entered into a Memorandum of Understanding (“MOU”) with
- 'Sun Safe' Study: Children Seek Shade if Availablehttps://practicaldermatology.com/news/20140812-sun_safe_study_children_seek_shade_if_available/2459147/A new study by the founder of Sun Safe Soccer reveals nearly two-thirds of children will use shade tents during soccer breaks without any prompting from coaches. The study, published in JAMA Dermatology, was conducted by Ian Maher, M.D., who developed the Sun Safe Soccer skin cancer preve
- Cynosure's PicoSure Laser Cleared by FDA for Acne Scarshttps://practicaldermatology.com/news/20140801-cynosure_announces_picosure_is_fda-cleared_to_treat_acne_scars/2459153/The FDA cleared the PicoSure picosecond laser to treat acne scars. "We are thrilled to announce that PicoSure, the world's most advanced laser technology for tattoo removal and benign pigmented lesions, has now received FDA-clearance to treat acne scar
- Innocutis Introduces Cold Sore Dissolvable Tablet to North American Markethttps://practicaldermatology.com/news/20140722-innocutis_introduces_cold_sore_dissolvable_tablet_to_north_american_market/2459160/Innocutis recently introduced Sitavig ®(ACYCLOVIR) 50mg Buccal Tablet to North American markets for the treatment of herpes labialis. Sitavig uses a proprietary delivery technology which consists of a tasteless and odorless tablet that sticks to the gum above the incisor tooth on the side of the lip
- Study: Dermatologists Preferred for Skin Cancer Evaluation and Treatmenthttps://practicaldermatology.com/news/20140722-study_dermatologists_preferred_for_skin_cancer_evaluation_and_treatment/2459161/Dermatologists are overwhelmingly the preferred health care provider for evaluating and treating skin cancer, according to a study published in the June issue of Dermatologic Surgery. In an online survey, respondents were asked their choice for evaluating a worrisome lesion on the face and for remov
- Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of Kerydin in the UShttps://practicaldermatology.com/news/20140721-anacor_pharmaceuticals_and_sandoz_enter_into_an_agreement_for_the_commercialization_of_kerydin_in_the_us/2459163/Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sandoz
- New Patient Education Service from Vivacare Helps Medical Professionals Deliver Health Education at the Point of Carehttps://practicaldermatology.com/news/20140716-new_patient_education_service_from_vivacare_helps_medical_professionals_deliver_health_education_at_the_point_of_care/2459166/Vivacare, a leading provider of patient education services for physicians, today announced a major upgrade to its free, web-based service and the opportunity for physician assistants, nurse practitioners and other medical professionals to enroll. In just minutes, physicians and other medical pr